Kiniksa Pharmaceuticals International, plc
For the period ended Dec 31, 2025. Filed Feb 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 24, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
| ITEM 9B. | OTHER INFORMATION. |
|---|
Trading Arrangements.
During the three months ended December 31, 2025, certain of our directors and officers entered into, modified or terminated contracts, instructions or written plans for the purchase or sale of our ordinary shares that are intended to satisfy the affirmative defense conditions specified in Rule 10b5-1(c) under the Exchange Act, as described below:
| · · · · Trading Arrangement · · | |||||||
|---|---|---|---|---|---|---|---|
| Name | Title | Action | Effective Date | Rule 10b5-1 | Non Rule 10b5-1 | Scheduled Expiration Date of Trading Plan(1) | Maximum Shares Subject to Trading Plan |
| Sanj K. Patel | Chairman and CEO | Adoption | October 31, 2025 | X | | December 31, 2026 | 564,182 |
| John Paolini | EVP, Chief Medical Officer | Adoption | November 18, 2025 | X | | November 19, 2026 | 98,424 |
| (1) | A trading arrangement may expire on an earlier date if all contemplated transactions are completed before such trading arrangement’s expiration date, upon termination by broker or the holder of the trading arrangement or as otherwise provided in the trading arrangement. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.